JHP Pharmaceuticals to launch new injectable product

JHP Pharmaceuticals, one of the global leaders in providing contract manufacturing services for sterile products, recently agreed to a deal with an unnamed pharmaceutical company to launch a new injectable.

The product will be in the cardiovascular realm, and JHP and its partner will produce both a clinical and commercial supply.

"We are pleased to serve this important customer and recognize that being selected to produce this injectable is based on our expertise with complex formulations coupled with our competence in both clinical supply and commercial supply," said Stuart Hinchen, president and CEO of JHP. "JHP's extensive experience working with products through their life cycle starting with clinical trials through approval, product launch and global commercialization provides customers with a measure of confidence allowing them to focus on their day-to-day business priorities."        

JHP Pharmaceuticals is headquartered in New Jersey, but has a plant in Rochester, Michigan, that is used as a sterile manufacturing facility. The plant employees about 300 people and includes a 171,000-square-foot production building and a 44,000-square-foot warehouse, according to the JHP website.